Inactivated influenza vaccine

Phase 3Vaccine

Sanofi

Inactivated influenza vaccine is one of 117 biologic programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

116

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

MelanomaActive, not recruiting

InfluenzaActive, not recruiting

LymphomaPreclinical

Active, not recruiting

MelanomaPhase 3

Active, not recruiting

InfluenzaPhase 3

Active, not recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Inactivated influenza vaccine

Sanofi

Phase 3

24 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Recruiting

Chronic Lymphocytic Leukemia

NCT03501576

Q4 2028

Post-ApprovalRecruiting

Immune Response

NCT07177417

Clinical

Trials by Indication[1]

Influenza14 trials

An Effectiveness Trial to Evaluate Protection of Children and Pregnant Women by Influenza Vaccine in Rural Bangladesh

Active, not recruiting·UUniversity of Bergen·Phase 4·NCT04998344·3,800 enrolled

Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine

Completed·HHualan Biological Engineering, Inc.·N/A·NCT01568788·600 enrolled

Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle

Completed·MMark Prausnitz·Phase 1·NCT02438423·100 enrolled

Show 11 more trials

Clinical Trial of the Inactivated Influenza Vaccine (0.25ml Formulation for Pediatric Use)

Completed·HHualan Biological Engineering, Inc.·Phase 3·NCT01554826·810 enrolled

Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age

Completed·PProtein Sciences Corporation·Phase 3·NCT02285998·9,003 enrolled

Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00091702·300 enrolled

Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived)

Completed·AAlachua Government Services, Inc.·Phase 1/2·NCT00289510·423 enrolled

Immunogenicity of Twice-annual Influenza Vaccination in Older Adults in Hong Kong

Active, not recruiting·TThe University of Hong Kong·Phase 4·NCT02957890·400 enrolled

A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine

Completed· Sanofi logo

Sanofi·Phase 2·NCT00343681·120 enrolled

Study of Live, Attenuated Influenza Vaccination in Preterm and Full-Term Infants

Terminated·UUniversity of Rochester·Phase 4·NCT01194297·3 enrolled

Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 Years

Completed·SSt. Louis University·Phase 4·NCT03101462·38 enrolled

The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)

Unknown status·NNova Immunotherapeutics Limited·Phase 1·NCT02500680·102 enrolled

A Study of a Live Intranasal Influenza Vaccine in Children With Cancer

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00906750·56 enrolled

Direct and Indirect Benefits of Influenza Vaccine Versus Placebo in Healthy Children

Completed·TThe University of Hong Kong·N/A·NCT00792051·2,800 enrolled

Immunogenicity3 trials

Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age

Completed·PProtein Sciences Corporation·Phase 3·NCT02290509·1,350 enrolled

A Study to Assess the Immunogenicity and Safety of CSL's 2009 / 2010 Formulation of Enzira® Vaccine in Healthy Volunteers

Completed·SSeqirus·Phase 4·NCT00888381·120 enrolled

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

Completed· Moderna logo

Moderna·Phase 2·NCT05606965·172 enrolled

Asthma1 trial

Safety of LAIV4 in Children With Asthma

Completed·VVanderbilt University Medical Center·Phase 4·NCT03600428·152 enrolled

Flu Vaccine1 trial

The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets

Completed·SStanford University·Phase 1·NCT03898986·18 enrolled

AIN1 trial

Yearly Strain Variation Study, 2010/2011

Completed·AAlachua Government Services, Inc.·Phase 3·NCT01157702·110 enrolled

4 more indications

Observational Study1 trial

Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults

Completed·PProtein Sciences Corporation··NCT02600585·254,648 enrolled

Immune Response1 trial

Characterizing the Human Airway Immune Response to FluMist Vaccination

Recruiting·WWashington University School of Medicine·Phase 4·NCT07177417·30 enrolled

Melanoma1 trial

Flu Vaccine Responses in the Setting of Melanoma Treatment

Active, not recruiting·UUniversity of Pennsylvania·Phase 4·NCT03315975·40 enrolled

Chronic Lymphocytic Leukemia1 trial

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

Recruiting·EEmory University··NCT03501576·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 24 trial records for Inactivated influenza vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Inactivated influenza vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Inactivated influenza vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Inactivated influenza vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2028

Trials by Indication[1]

Influenza14 trials

Immunogenicity3 trials

Asthma1 trial

Flu Vaccine1 trial

AIN1 trial

Observational Study1 trial

Immune Response1 trial

Melanoma1 trial

Chronic Lymphocytic Leukemia1 trial

References

Drug Info

Quick Facts

Related News